Invectys appoints Timothy Papp as its Chief Financial Officer Houston, Texas, USA, May 12, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet...

Invectys, Inc appoints Biopharma Veteran, Praveen Tyle, PhD as President & CEO Houston, TX, USA, May 04, 2021 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...

Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019 No safety concerns identified; no significant overlap of or unexpected toxicities65% overall ORR with 9% CR (RECIST 1.1) maintainedPreliminary PFS of 12.3 monthsChanges in T cell populations similar...

Provectus Announces Preliminary Results from Phase 1 Trial of PV-10 for Treatment of Metastatic Neuroendocrine Tumors at ASCO 2019 No safety concerns identified50% ORR and 83% disease control of injected lesionsStable Chromogranin A responses and quality of life scores for nearly all subjects KNOXVILLE, TN, June 03, 2019 ...